Pipeline dossier

NIH & clinical-trial pipeline signals for AbbVie Inc. (ABBV)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for ABBV, mapped to public ticker ABBV (CIK 0001551152). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingABBV35% conf

AbbVie Inc. (ABBV) — PHASE2 protocol updated 7 days ago

Upstream (observed)
Clinical trial status (PHASE2) — Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Recent SEC 8-K filings

2026-11-02 — 8-K 5.02 view ↗
2026-10-30 — 8-K 2.02,9.01 view ↗
2026-10-15 — 8-K 5.02 view ↗
2026-10-05 — 8-K 2.02,9.01 view ↗
2026-09-03 — 8-K 7.01,9.01 view ↗

JSON API for this entity →